Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
2.280
+0.470 (25.97%)
Mar 23, 2026, 2:41 PM EDT - Market open
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change
-1
Growth
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$4,230,833
Market Cap
137.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -1 | -11.11% |
| Sep 30, 2025 | 8 | -1 | -11.11% |
| Jun 30, 2025 | 8 | -2 | -20.00% |
| Mar 31, 2025 | 8 | -2 | -20.00% |
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Sep 30, 2024 | 9 | -3 | -25.00% |
| Jun 30, 2024 | 10 | -5 | -33.33% |
| Mar 31, 2024 | 10 | -5 | -33.33% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Sep 30, 2023 | 12 | -3 | -20.00% |
| Jun 30, 2023 | 15 | 1 | 7.14% |
| Mar 31, 2023 | 15 | 1 | 7.14% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Sep 30, 2022 | 15 | 4 | 36.36% |
| Jun 30, 2022 | 14 | 4 | 40.00% |
| Mar 31, 2022 | 14 | 6 | 75.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Sep 30, 2021 | 11 | 0 | - |
| Jun 30, 2021 | 10 | 0 | - |
| Mar 31, 2021 | 8 | -7 | -46.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Gossamer Bio | 162 |
| Inovio Pharmaceuticals | 134 |
| Rani Therapeutics Holdings | 106 |
| Oncolytics Biotech | 28 |
| Genelux | 24 |
| TuHURA Biosciences | 19 |
ALDX News
- 4 days ago - What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
- 5 days ago - Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 6 days ago - US FDA declines to approve Aldeyra's drug for eye disorder - Reuters
- 6 days ago - Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease - Business Wire
- 4 weeks ago - Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
- 3 months ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript - Seeking Alpha
- 3 months ago - Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease - Business Wire